Insulin Resistance and Constant Hunger in New Jersey
Published by New Jersey Trim Clinic · Updated 2025-09-08
The Hidden Driver Behind Constant Hunger
If you are constantly hungry no matter what you eat, insulin resistance may be the reason. It is one of the most common — and most underdiagnosed — drivers of weight gain in New Jersey adults.
When your cells stop responding properly to insulin, your body keeps producing more of it. High insulin levels block fat burning and keep hunger signals turned on, even right after meals.
👉 Check If You Qualify in 2 Minutes
How It Builds Over Years
Insulin resistance does not happen overnight. It builds gradually from years of high-carb eating, sedentary work (NJ commuter life is brutal for this), poor sleep, and chronic stress. By the time you feel "always hungry," your metabolism has already been struggling for a long time.
Common signs: belly fat that will not go, energy crashes after meals, cravings for sweets, and weight that keeps climbing despite eating less.
Why GLP-1 Therapy Works
GLP-1 medications improve insulin sensitivity directly. They lower fasting insulin levels, stabilize blood sugar, and reduce the constant hunger that comes with insulin resistance. NJ patients often see improvements in energy and cravings within weeks — long before significant weight loss shows up.
👉 Start Losing Weight This Week
Get Evaluated By a Real Physician
A board-certified physician evaluates your full picture — labs, history, BMI, and goals. $149/month all-inclusive, telehealth across NJ.
MEDICAL SOURCES & FURTHER READING
Read the source alongside the specific topic it supports. These independent sources do not endorse New Jersey Trim Clinic. Research findings are not a prediction of your results.
- NIH/NIDDK — Prescription Medications to Treat Overweight & Obesity
Supports: Weight-management medication requires individualized prescribing; eligibility, benefits, risks and ongoing treatment should be discussed with a healthcare professional. Nutrition and physical activity remain part of treatment.
- Mayo Clinic — Prescription weight-loss drugs
Supports: Prescription weight-loss medicines have eligibility restrictions, potential side effects and a need for professional oversight; they are used alongside lifestyle measures.
- Cleveland Clinic — GLP-1 Agonists
Supports: GLP-1 receptor agonists act on appetite and satiety, help regulate blood glucose and can slow stomach emptying. Common adverse effects include nausea, vomiting and diarrhea.
Evidence limits: The extent and duration of effects differ by drug, dose and individual; a general mechanism does not establish a guaranteed response.
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Supports: A randomized study reported reduced hunger, food cravings and energy intake, and improved control of eating with semaglutide.
Evidence limits: This study does not establish a diagnosis of 'food noise', prove that all intrusive food thoughts have one cause, or show that every patient will experience relief. It found no evidence of delayed gastric emptying at week 20 using its indirect test.
- NIH/NIDDK — Factors Affecting Weight & Health
Supports: Weight is influenced by lifestyle, sleep, medicines, health conditions, family history and other factors; insufficient sleep can affect hunger.
Evidence limits: This general guidance does not establish the cause of an individual patient's cravings, emotional eating, insulin resistance or weight changes.
- FDA — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Supports: Compounded GLP-1 drugs are not FDA-approved. FDA describes dosing, quality, storage and other safety concerns, and advises that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.
Evidence limits: Pharmacy registration is not FDA approval of a compounded product. Clinical trials of approved drugs do not establish the safety or effectiveness of compounded formulations.
RESEARCH & REFERENCES
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. Diabetes, Obesity and Metabolism. 2021.
Research published in Diabetes, Obesity and Metabolism reported improvements in appetite and control of eating in a 20-week trial of semaglutide in adults with obesity.
General education is not individualized medical advice. Prescription treatment requires evaluation by a licensed provider. Eligibility, medication and dosing depend on individual circumstances.
Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. Published studies of approved medications do not establish equivalent safety or effectiveness of compounded products.